FY2026 medical budget lines and team-level resource capacity. All figures USD; FY2026 exchange-rate snapshot of 2 Jan 2026.
Planned
Committed
Actual
Forecast at year end
Overrun-risk rule (MET-071): committed > planned, or actual ÷ planned > 0.75 × 1.05 = 78.75% with 71% of the fiscal year elapsed. Forecast is a straight-line assumption: actual ÷ 0.71. It ignores seasonality and known one-off commitments.
USD millions
| Product | Planned | Committed | Actual |
|---|---|---|---|
| Lumeva | $3.6M | $3.51M | $2.84M |
USD millions, sorted by planned
Largest category: Personnel ($1.69M planned). 5 categories in the current filter.
MET-070 monthly history (Global, % of planned) against an even 1/12-per-month plan line. Filters do not apply to this series.
Latest: 71% consumed by Sep versus 75% on the straight line. Consumption above the line means spend is running ahead of an even phasing.
| Line | Product | Region | Function | Category | Initiative | Vendor | Planned | Committed | Actual | Variance | Consumed | Risk |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| BL-020 | Lumeva | Global | Field Medical | Personnel | — | — | $1.4M | $1.4M | $1.0M | $340k | 75% | On plan |
| BL-021 | Lumeva | Global | Medical Communications | Publication | INI-0301 | — | $180k | $170k | $128k | $52k | 71% | On plan |
| BL-022 | Lumeva | Global | Medical Communications | Congress | INI-0302 | — | $340k | $320k | $241k | $99k | 71% | On plan |
| BL-023 | Lumeva | Global | Evidence Generation | Research | — | — | $1.1M | $1.1M | $1.0M | $108k | 91% | Overrun risk |
| BL-024 | Lumeva | Global | Field Medical | Medical education | — | — | $240k | $210k | $160k | $80k | 67% | On plan |
| BL-025 | Lumeva | Global | Medical Information | Personnel | INI-0303 | — | $340k | $340k | $262k | $78k | 77% | On plan |
Team-level analytics only
8 of 10 teams have demand above capacity.
| Team | Region | Function | Capacity FTE | Demand FTE | Utilisation | Contractor FTE | Critical roles | Allocations by initiative |
|---|---|---|---|---|---|---|---|---|
| Field Medical — US Oncology | North America | Field Medical | 8 | 8.6 | 108% | 0 |
| |
| Field Medical — EU Oncology | Europe | Field Medical | 10 | 10.2 | 102% | 1 | — | |
| Field Medical — Japan | Asia-Pacific | Field Medical | 1 | 2 | 200% | 0 |
|
|
| Field Medical — Nephrology | Europe | Field Medical | 3 | 3.4 | 113% | 0 |
| |
| Field Medical — Neurology | Global | Field Medical | 6 | 5.1 | 85% | 0 | — | |
| Medical Communications | Global | Medical Communications | 5 | 6.1 | 122% | 2 |
| |
| Medical Information | Global | Medical Information | 9 | 9.8 | 109% | 1 | — | |
| Evidence Generation & HEOR | Global | Evidence Generation | 4 | 4.9 | 123% | 1 |
| |
| Medical Operations | Global | Medical Operations | 3 | 2.8 | 93% | 0 | — | Not allocated to initiatives |
| Compliance & Quality (MA-aligned) | Global | Compliance | 1 | 1.7 | 170% | 0 |
| Not allocated to initiatives |